Literature DB >> 19902548

TLR9 mRNA expression is upregulated in patients with active ulcerative colitis.

Fausto Sánchez-Muñoz, Gabriela C Fonseca-Camarillo, Marco A Villeda-Ramirez, Rafael Barreto-Zuniga, Rafael Bojalil, Aarón Domínguez-Lopez, Misael Uribe, Jesus K Yamamoto-Furusho.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 19902548     DOI： 10.1002/ibd.21155

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN： 1078-0998            Impact factor:   5.325


× No keyword cloud information.
  8 in total

1.  Cathelicidin signaling via the Toll-like receptor protects against colitis in mice.

Authors:  Hon Wai Koon; David Q Shih; Jeremy Chen; Kyriaki Bakirtzi; Tressia C Hing; Ivy Law; Samantha Ho; Ryan Ichikawa; Dezheng Zhao; Hua Xu; Richard Gallo; Paul Dempsey; Genhong Cheng; Stephan R Targan; Charalabos Pothoulakis
Journal:  Gastroenterology       Date:  2011-07-14       Impact factor: 22.682

2.  Basic and translational understandings of microbial recognition by toll-like receptors in the intestine.

Authors:  Sang Hoon Rhee
Journal:  J Neurogastroenterol Motil       Date:  2011-01-26       Impact factor: 4.924

3.  Preconditioning with intravenous colitic cell-free DNA prevents DSS-colitis by altering TLR9-associated gene expression profile.

Authors:  Györgyi Műzes; Ferenc Sipos; István Fűri; Miklós Constantinovits; Sándor Spisák; Barnabás Wichmann; Gábor Valcz; Zsolt Tulassay; Béla Molnár
Journal:  Dig Dis Sci       Date:  2014-09-13       Impact factor: 3.199

4.  Transcript levels of Toll-Like Receptors 5, 8 and 9 correlate with inflammatory activity in Ulcerative Colitis.

Authors:  Fausto Sánchez-Muñoz; Gabriela Fonseca-Camarillo; Marco A Villeda-Ramírez; Elizabeth Miranda-Pérez; Edgar J Mendivil; Rafael Barreto-Zúñiga; Misael Uribe; Rafael Bojalil; Aarón Domínguez-López; Jesús K Yamamoto-Furusho
Journal:  BMC Gastroenterol       Date:  2011-12-20       Impact factor: 3.067

Review 5.  The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease.

Authors:  Grainne Holleran; Loris Lopetuso; Valentina Petito; Cristina Graziani; Gianluca Ianiro; Deirdre McNamara; Antonio Gasbarrini; Franco Scaldaferri
Journal:  Int J Mol Sci       Date:  2017-09-21       Impact factor: 5.923

6.  The TLR9 Agonist Cobitolimod Induces IL10-Producing Wound Healing Macrophages and Regulatory T Cells in Ulcerative Colitis.

Authors:  Heike Schmitt; Julia Ulmschneider; Ulrike Billmeier; Michael Vieth; Patrizio Scarozza; Sophia Sonnewald; Stephen Reid; Imke Atreya; Timo Rath; Sebastian Zundler; Melanie Langheinrich; Jürgen Schüttler; Arndt Hartmann; Thomas Winkler; Charlotte Admyre; Thomas Knittel; Christine Dieterich Johansson; Arezou Zargari; Markus F Neurath; Raja Atreya
Journal:  J Crohns Colitis       Date:  2020-05-21       Impact factor: 9.071

Review 7.  Intestinal Organoids as a Tool for Inflammatory Bowel Disease Research.

Authors:  Hamish C K Angus; A Grant Butt; Michael Schultz; Roslyn A Kemp
Journal:  Front Med (Lausanne)       Date:  2020-01-17

8.  Clinical Effects of a Topically Applied Toll-like Receptor 9 Agonist in Active Moderate-to-Severe Ulcerative Colitis.

Authors:  Raja Atreya; Stuart Bloom; Franco Scaldaferri; Viviana Gerardi; Charlotte Admyre; Åsa Karlsson; Thomas Knittel; Jan Kowalski; Milan Lukas; Robert Löfberg; Stephane Nancey; Robert Petryka; Grazyna Rydzewska; Robert Schnabel; Ursula Seidler; Markus F Neurath; Christopher Hawkey
Journal:  J Crohns Colitis       Date:  2016-05-20       Impact factor: 9.071
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.